About Longboard Pharmaceutical
Longboard Pharmaceutical is a company based in San Diego (United States) founded in 2020 was acquired by Lundbeck in October 2024. Longboard Pharmaceutical has raised $56 million across 1 funding round from investors including T. Rowe Price, Lundbeck and Farallon Capital Management. The company has 50 employees as of February 29, 2024. Longboard Pharmaceutical offers products and services including GPCR Therapies. Longboard Pharmaceutical operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Harmony Biosciences, among others.
- Headquarter San Diego, United States
- Employees 50 as on 29 Feb, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Longboard Pharmaceuticals, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$54.42 M (USD)-24as on Dec 31, 2023
-
EBITDA
-$56.76 M (USD)-27as on Dec 31, 2023
-
Total Equity Funding
$56 M (USD)
in 1 rounds
-
Latest Funding Round
$56 M (USD), Series C
Oct 28, 2020
-
Investors
T. Rowe Price
& 3 more
-
Employee Count
50
as on Feb 29, 2024
-
Acquired by
Lundbeck
(Oct 14, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Longboard Pharmaceutical
Longboard Pharmaceutical offers a comprehensive portfolio of products and services, including GPCR Therapies.
Pipeline of neurological medicines targeting GPCR for rare diseases treatment.
People of Longboard Pharmaceutical
Unlock access to complete
Unlock access to complete
Funding Insights of Longboard Pharmaceutical
Longboard Pharmaceutical has successfully raised a total of $56M through 1 strategic funding round. The most recent funding activity was a Series C round of $56 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Longboard Pharmaceutical
Longboard Pharmaceutical has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include T. Rowe Price, Lundbeck and Farallon Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Late-stage life sciences investments are managed via VC and PE.
|
Locked | Locked | Locked | |
|
Multiple investment strategies are pursued by this hedge fund.
|
Locked | Locked | Locked | |
|
Diversified asset management services are provided to investors globally.
|
Locked | Locked | Locked |
Investor details for Longboard Pharmaceutical
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Longboard Pharmaceutical
Investment portfolio details for Longboard Pharmaceutical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Longboard Pharmaceutical
Detailed financials for Longboard Pharmaceutical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Longboard Pharmaceutical Comparisons
Peer comparison for Longboard Pharmaceutical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Longboard Pharmaceutical
Longboard Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Harmony Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for rare neurological diseases
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
Detailed competitors of Longboard Pharmaceutical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Longboard Pharmaceutical
Complete news archive for Longboard Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Longboard Pharmaceutical
Longboard Pharmaceutical was founded in 2020.
Longboard Pharmaceutical is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Kevin Lind is the current CEO of Longboard Pharmaceutical.
Longboard Pharmaceutical is a funded company, having raised a total of $56M across 1 funding round to date.
As of Feb 29, 2024, the latest employee count at Longboard Pharmaceutical is 50.
Provider of therapeutic solution for treating rare neurological diseases. The company proprietary pipeline includes LP352, which is a 5-HT2C for epileptic encephalopathies; LP143 which is a cannabinoid type 2 receptor (CB2), and LP659, which is a selective S1P receptor modulator and can be used in the treatment of Epilepsies, ALS, PD, and Multiple CNS neuroinflammatory disorders.
Longboard Pharmaceutical's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Longboard Pharmaceutical offers GPCR Therapies.
Longboard Pharmaceutical has 4 investors. Key investors include T. Rowe Price, Lundbeck, Farallon Capital Management, and HBM Partners.